These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 28574654)
21. Von hippel-lindau disease: a genetic and clinical review. Haddad NM; Cavallerano JD; Silva PS Semin Ophthalmol; 2013; 28(5-6):377-86. PubMed ID: 24138046 [TBL] [Abstract][Full Text] [Related]
22. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Osada R; Horiuchi A; Kikuchi N; Yoshida J; Hayashi A; Ota M; Katsuyama Y; Melillo G; Konishi I Hum Pathol; 2007 Sep; 38(9):1310-20. PubMed ID: 17555795 [TBL] [Abstract][Full Text] [Related]
23. Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1alpha expression. Jensen RL; Gillespie D; House P; Layfield L; Shelton C J Neurosurg; 2004 Mar; 100(3):488-97. PubMed ID: 15035285 [TBL] [Abstract][Full Text] [Related]
24. Loss of heterozygosity reveals non-VHL allelic loss in hemangioblastomas at 22q13. Beckner ME; Sasatomi E; Swalsky PA; Hamilton RL; Pollack IF; Finkelstein SD Hum Pathol; 2004 Sep; 35(9):1105-11. PubMed ID: 15343513 [TBL] [Abstract][Full Text] [Related]
25. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
26. A Comprehensive Procedure to Evaluate the In Vitro Performance of the Putative Hemangioblastoma Neovascularization Using the Spheroid Sprouting Assay. Wang Y; Chen D; Chen M; Ji K; Ma D; Zhou L J Vis Exp; 2018 Apr; (134):. PubMed ID: 29708531 [TBL] [Abstract][Full Text] [Related]
28. Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in Vhl knockout mice. Kleymenova E; Everitt JI; Pluta L; Portis M; Gnarra JR; Walker CL Carcinogenesis; 2004 Mar; 25(3):309-15. PubMed ID: 14604887 [TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766 [TBL] [Abstract][Full Text] [Related]
30. PARS PLANA VITRECTOMY IN ADVANCED CASES OF VON HIPPEL-LINDAU EYE DISEASE. Krzystolik K; Stopa M; Kuprjanowicz L; Drobek-Slowik M; Cybulski C; Jakubowska A; Gronwald J; Lubiński J; Lubiński W Retina; 2016 Feb; 36(2):325-34. PubMed ID: 26308528 [TBL] [Abstract][Full Text] [Related]
31. Overexpression of von Hippel-Lindau tumor suppressor protein and antisense HIF-1alpha eradicates gliomas. Sun X; Liu M; Wei Y; Liu F; Zhi X; Xu R; Krissansen GW Cancer Gene Ther; 2006 Apr; 13(4):428-35. PubMed ID: 16211089 [TBL] [Abstract][Full Text] [Related]
32. Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease. Wittström E; Nordling M; Andréasson S Ophthalmic Genet; 2014 Jun; 35(2):91-106. PubMed ID: 24555745 [TBL] [Abstract][Full Text] [Related]
33. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414 [TBL] [Abstract][Full Text] [Related]
34. VHL and PTEN loss coordinate to promote mouse liver vascular lesions. Chen S; Sanford CA; Sun J; Choi V; Van Dyke T; Samulski RJ; Rathmell WK Angiogenesis; 2010 Mar; 13(1):59-69. PubMed ID: 20221685 [TBL] [Abstract][Full Text] [Related]
35. The HIF and other quandaries in VHL disease. Tarade D; Ohh M Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400 [TBL] [Abstract][Full Text] [Related]
36. The von Hippel-Lindau tumor suppressor gene. Kondo K; Kaelin WG Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528 [TBL] [Abstract][Full Text] [Related]
37. Von Hippel-Lindau disease: a single gene, several hereditary tumors. Crespigio J; Berbel LCL; Dias MA; Berbel RF; Pereira SS; Pignatelli D; Mazzuco TL J Endocrinol Invest; 2018 Jan; 41(1):21-31. PubMed ID: 28589383 [TBL] [Abstract][Full Text] [Related]
38. Fibrosis and hypoxia-inducible factor-1α-dependent tumors of the soft tissue on loss of von Hippel-Lindau in mesenchymal progenitors. Mangiavini L; Merceron C; Araldi E; Khatri R; Gerard-O'Riley R; Wilson TL; Sandusky G; Abadie J; Lyons KM; Giaccia AJ; Schipani E Am J Pathol; 2015 Nov; 185(11):3090-101. PubMed ID: 26348575 [TBL] [Abstract][Full Text] [Related]
39. [Genetic analysis of a family with Von Hippel-Lindau syndrome]. Lafuente-Sanchis A; Cuevas JM; Alemany P; Cremades A; Zúñiga Á Rev Esp Patol; 2017; 50(1):64-67. PubMed ID: 29179968 [TBL] [Abstract][Full Text] [Related]
40. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)]. Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]